- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00167999
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
March 14, 2007 updated by: Wyeth is now a wholly owned subsidiary of Pfizer
Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 133-792
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Eligible patients of either sex, 15 years of age or older
- Patients who are admitted to the department of hematology and oncology
- Provide written informed consent
Exclusion Criteria:
- Patients who have hypersensitivity to β-lactam antibiotics
- Female who are pregnant or breast-feeding
- Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2005
Study Registration Dates
First Submitted
September 11, 2005
First Submitted That Met QC Criteria
September 11, 2005
First Posted (Estimate)
September 14, 2005
Study Record Updates
Last Update Posted (Estimate)
March 15, 2007
Last Update Submitted That Met QC Criteria
March 14, 2007
Last Verified
March 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Gram-Negative Bacterial Infections
- Bacterial Infections and Mycoses
- Enterobacteriaceae Infections
- Infections
- Communicable Diseases
- Bacterial Infections
- Escherichia coli Infections
- Klebsiella Infections
- Gram-Positive Bacterial Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- beta-Lactamase Inhibitors
- Piperacillin
- Tazobactam
- Piperacillin, Tazobactam Drug Combination
Other Study ID Numbers
- 0910X-101676
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gram-Positive Bacterial Infections
-
Ministry of Health, RwandaUnknownDisease Due to Gram-positive BacteriaRwanda
-
Melinta Therapeutics, LLCRecruitingGram Positive Bacterial InfectionsUnited States
-
Cubist Pharmaceuticals LLCCompletedGram-positive Bacterial InfectionsUnited States
-
Imperial College LondonHammersmith Hospitals NHS TrustCompletedStaphylococcal Infections | Gram-positive Bacterial InfectionsUnited Kingdom
-
Cubist Pharmaceuticals LLCCompleted
-
NovartisNovartis VaccinesCompletedBacterial Infection | Streptococcal Infection | Gram-positive Bacterial InfectionBelgium, Canada
-
Cumberland PharmaceuticalsCompletedInfections, Gram-positive BacterialUnited States
-
Cumberland PharmaceuticalsTerminatedGram-Positive Bacterial InfectionsUnited States
-
Universitaire Ziekenhuizen KU LeuvenCompletedGram-Positive Bacterial InfectionsBelgium
-
PfizerAventis PharmaceuticalsTerminatedGram-Positive Bacterial InfectionsUnited States
Clinical Trials on piperacillin-tazobactam
-
St. Justine's HospitalUnknown
-
Fundación Pública Andaluza para la gestión de la...Hospital Son Espases; Hospital Universitario Virgen Macarena; Hospital Son Llatzer and other collaboratorsCompletedPseudomonas Aeruginosa InfectionSpain
-
Ain Shams UniversityCompletedGram-Negative InfectionsEgypt
-
Karolinska InstitutetCompletedCholecystitis, AcuteSweden
-
European Organisation for Research and Treatment...CompletedLymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Unspecified Adult Solid Tumor, Protocol Specific | Infection | Multiple Myeloma and Plasma Cell Neoplasm | Fever, Sweats, and Hot Flashes | Bone Marrow SuppressionSwitzerland, United States, Canada, United Kingdom, Belgium, Israel, Slovakia, Finland, Germany, France, Turkey, Czech Republic, Greece
-
University Hospital, RouenNot yet recruitingPancreaticoduodenectomy | Antibiotherapy
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDiabetes Mellitus | Diabetic Foot
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedUrinary InfectionsSpain
-
Nabriva Therapeutics AGMedpace, Inc.CompletedAcute Pyelonephritis | Urinary Tract Infection Complicated | Urinary Tract Infection SymptomaticPoland, Ukraine, Belarus, Bulgaria, Romania, Greece, United States, Russian Federation, Hungary, Lithuania, Slovakia, Czechia, Latvia, Croatia, Georgia, Estonia
-
Institute of Liver and Biliary Sciences, IndiaCompletedPostoperative Infection | Antibiotic ProphylaxisIndia